Jean-Jacques Bienaimé, BioMarin CEO (via YouTube)
October 7, 2022 07:25 AM EDT
People

Bio­Marin lays off 120 staffers to 'sim­pli­fy' the com­pa­ny while FDA re­views its big gene ther­a­py

Amber Tong

By the time the FDA hands down its de­ci­sion on val­rox, Bio­Marin will be a dif­fer­ent com­pa­ny — lit­er­al­ly.

The biotech is lay­ing off about 120 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times